Novel Molecular Signaling Method and System for Molecular Communication
  in Human Body by Al-Helali, AbdulAziz et al.
1 
> REPLACE THIS LINE WITH YOUR PAPER IDENTIFICATION NUMBER (DOUBLE-CLICK HERE TO EDIT) < 
 
  
Abstract— For millions of years, MC has been the primary 
method of communication in living organisms, cells, and the 
human body. Recently, Molecular Communication (MC) has been 
recognized as an enabling technology for nanonetworks [1] where 
MC is envisioned to enable nanorobots to achieve sophisticated 
and complex tasks in the human body for promising medical 
applications. Many MC methods that can be applied in the human 
body have been proposed and modeled in the literature. However, 
none of them can be used to convey information between distant 
points that are separated by body fluids, tissues, or placed in 
different organs. In this paper, we propose a new method and 
system for Molecular Communication in the Body, denoted 
MoSiMe and MoCoBo, respectively. The method takes advantage 
of how the absorption, distribution, metabolization, and 
elimination (ADME) bodily processes affects drugs, referred to as 
Pharmacokinetics (PK) in pharmacology, to enable MC between 
any points of the human body regardless of their distance even if 
they are in different parts of the body and separated by tissues and 
fluids. The architecture, design and components of the MoCoBo 
system and MoSiMe method are described and different 
transmitter designs, including a novel passive transmitter design 
for the first time in telecommunications, are introduced. An 
analytical model for the body channel is derived and validated 
with respect to existing human and animal tests. The model 
captures the ADME bodily processes that affect the kinetics of 
substances administered to the body. Additionally, an 
experimental MoCoBo proof of concept platform, capable of 
reliably sending and receiving a stream of bits between a 
transmitter and a receiver, is built and validated against clinical 
trials, animal tests and analytical models. The introduced platform 
can also be utilized to test modulation techniques and designs for 
new MoCoBo transmitters and receivers. 
Index Terms— communication systems, molecular 
communication in body, molecular communication via ADME, 
nanonetworks. 
I. INTRODUCTION 
 In recent years, there is an increased interest in Molecular 
Communication (MC) since it has been recognized as an 
enabling technology for nanonetworks [1]. Unlike classical  
 
forms of communications, such as electro-magnetic 
communication, MC uses molecules to convey information 
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between the points of communication link, which for example 
could be a swarm of robots or larger scale devices that uses MC 
as an alternative link when classical forms of communications 
are not suitable. 
For millions of years, MC has been the primary method of 
communication in living organisms, cells, and the human body. 
Cell signaling [2] and quorum sensing [3] are two examples of 
MC. In cell signaling, cells exchange molecules between each 
other to achieve specific goals such as control of growth and 
cell functionalities. Similarly, bacteria use MC in a process 
called quorum sensing to regulate expression of genes in 
response to the concentration of specific molecules called 
autoinducers which are used for managing many physiological 
activities such as interdependence, motility, and virulence [3]. 
Quorum sensing enables bacteria to communicate within a 
community and across species which give them the abilities of 
more developed organisms by taking coordinating actions [3]. 
Like quorum sensing in bacteria, by forming body area 
nanonetworks [4], MC is envisioned to enable nanorobots to 
achieve sophisticated and complex tasks in the human body for 
promising medical purposes such as disease detection, and 
targeted drug delivery [5]. For example, in disease detection, 
bacteriobots [6], which are made of modified flagellated 
bacteria, are used in targeting and treating tumor cells. The 
effectiveness of such bacteriobots can be greatly improved to 
perform tasks such as tumor early detection if they are 
interconnected [7] in a mobile ad hoc molecular nanonetwork 
(MAMNET) [8] to exchange information. 
Many MC methods between nanorobots in the human body 
have been proposed and modeled in the literature. These 
methods can be broadly classified, based on distance, into short 
(nm-µm), medium (µm-mm), and long range (mm-m) [9]. 
Existing short and medium range methods such as free diffusion 
[10] and bacteria assisted propagation [11] can be used for 
communication in the scale of a few millimeters or less. 
Therefore, they limit the range of communication in one place 
such as inside a cell, tissue, or an organ. On the other hand, long 
range MC methods such as diffusion with drift [10] uses the 
blood as medium to carry the information molecules which 
limits their scope of communication inside the circulatory 
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system. They cannot be used if communicating ends do not 
have direct access to the blood stream.  
The human body spans larger distances and exhibits many 
factors other than diffusion and drift that influence MC, such as 
ADME. A wider and more comprehensive method of MC is 
needed to enable communication between any points across the 
body systems. Therefore, we propose a new Molecular 
Signaling Method in the body, denoted MoSiMe. The method 
takes advantage of how the ADME bodily processes affects 
drugs, referred to as Pharmacokinetics (PK) in pharmacology 
[12], to enable MC between any points of the human body 
regardless of their distance even if they are in different parts of 
the body and separated by tissues and fluids. For example, it 
can be used to convey information from a transmitter in the gut 
and a receiver in the heart. 
We further describe the architecture, design, and different 
components of a system of Molecular Communication in 
Human Body (MoCoBo) with its underlaying MoSiMe. The 
system is capable of reliably communicating information in the 
body using molecules. An analytical model for the body 
channel is derived and an experimental platform is built to 
prove the concept of using MC in the body, which also allows 
the testing of new MC components such transmitters, receivers, 
and modulation techniques. The experimental platform is 
implemented and verified against clinical trials, animal tests, 
and analytical models.  
The paper contributions can be summarized as follows: 
• We propose MoSiMe and use it to develop the MoCoBo 
system, which includes the system architecture and various 
active and passive MoCoBo transmitters and receivers. We 
show the functionality of MoCoBo analytically and 
experimentally. To the best of our knowledge, we are the 
first to introduce a fully functional molecular 
communication system in the human body, derive an 
analytical model that accurately characterizes it, and build 
a practical experimental platform to test it. The system and 
method can be characterized as a Linear Time Invariant 
(LTI) system and communication engineering tools are 
utilized to derive its response and predict its behavior. Our 
work provides a simple MC signaling method that avoids 
the challenges of using chemical signals such as in [13] 
which is primarily attributed to the utilization of two 
chemicals to perform MC. Complex chemical interactions 
complicates the characterization of the system and forces 
the use of complex detection algorithms that could be 
difficult to implement at receivers with limited processing 
capabilities. Furthermore, our work is not limited to the use 
of a single substance for realizing MC such as in [14], 
where the proposed system relies solely on magnetized 
nano particles and limits the selection choices of biosensors 
for detecting nano particles without providing an analytical 
model or verifying the method for use in the human body.   
• We provide an analytical model for the MoCoBo system 
and method, by deriving the impulse response and channel 
model for the human body, which considers the effects of 
natural body processes on the channel. Unlike previous 
research efforts, we present a physical channel model for 
the human body that captures natural processes including 
absorption, distribution, elimination, and excretions. The 
presented model, which is adapted from Pharmacokinetics 
(PK), a branch of pharmacology that studies how drugs 
move within the body [12], also predicts molecule 
concentration changes at all parts of the body. While PK 
models simulate the concentration of drugs in the body 
over time, they are not adequate for designing, testing and 
analyzing a MC communication system. However, 
adapting PK models allows for modeling the entire body as 
an LTI system, thus enabling the derivation of the body 
impulse response and application of communication 
engineering tools to characterize the MC physical channel 
within the body. All routes of administration are modelled 
by intravenous and extravascular models. In particular, the 
extravascular parameters can be accommodated to any 
route to the body that does not have access to blood stream 
such as oral, inhaling, or muscular routes. 
• We have created a MoCoBo experimental platform that 
mimics the natural process of the body to prove the concept 
of MC in human body. It can also be used for testing and 
improving future MoCoBo transmitters, receivers, channel 
codes, and modulation techniques. We have validated the 
experimental platform against clinical trials, animal tests, 
and the derived analytical models. 
The rest of this paper is organized as follows. Section II 
reviews relevant literature. Section III provides an overview of 
pharmacokinetics and Section IV presents the body impulse 
response. Section V discusses the proposed MoCoBo system 
and method while the MoCoBo experimental platform is 
discussed in Section VI. The derived physical channel model 
and the experimental platform along with the MoCoBo system 
and method are validated in section VII. Summary, conclusions 
and future work are provided in Section VIII. 
II. LITERATURE REVIEW 
A. MC Channel Characterization 
Many models have been developed in the literature to 
characterize MC physical channels and propagation. These 
models can be broadly classified, based on distance, into short, 
medium, and long range channel models [9]. Some of the short 
and medium range models are presented in [13-19]. 
Specifically, models for propagation via diffusion and flow 
assisted diffusion are presented in [10] and [15], while on chip 
propagation via active transport is discussed in [16] and [17], 
and bacteria assisted propagation is proposed in [11]. On the 
other hand, calcium signaling via gap junctions is modeled for 
different body tissues in [18], and MC channel models for 
different flow-based microfluidic channels were derived in 
[19].  
While short and medium range channel models capture the 
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dynamics of MC channels in the scale of a few millimeter or 
less, the human body spans larger distances and exhibits other 
factors that influence MC channels such as chemical reactions, 
absorption, distribution, metabolization, and excretion. 
Therefore, such models cannot be relied on for MC channel 
modeling the human body.  
In [20], a long range MC channel model for the 
cardiovascular system is presented. The model estimates the 
blood velocity profile and the delivery rate of injected 
molecules (particulate drugs) at different locations in the blood 
vessel network using physiological parameters such as the 
blood pressure profile, cardiac input, and heartbeat stroke 
volume and rate profile. However, it does not incorporate the 
effect of body processes such as molecule elimination by the 
kidney or transformation by the liver. In addition, it does not 
describe what happens to molecules in other body tissues 
outside the cardiovascular network. Furthermore, it assumes 
molecules are input into the body intravenously and does not 
consider other routes of administration such as oral or muscular 
administration.  
B. MC Experimental Platforms 
 Clinical trials or even animal tests are prohibitively 
expensive and difficult to access for engineering research of 
MC in body. So far, very few experimental platforms and 
testbeds have been built to demonstrate and test MC systems in 
gaseous or aqueous mediums. In gaseous mediums, the first 
experimental platform that realized manmade MC is presented 
in [21] and [22].  It employs MC to send text messages in the 
air over a few meters for the first time. In [23], the platform is 
used to compare the performance of MC and electromagnetic 
waves in infrastructure monitoring applications where it 
demonstrated that MC connections remained successful while 
electromagnetic waves connections failed in metallic air ducts. 
Based on the work of [21], a new platform that supports 
multiple input multiple output communication is developed in 
[24]. Similarly but in aqueous environments, in [13]  and  [14] 
two testbeds are built to test MC in vessels. In [13], a multi-
chemical MC platform that uses acids and bases to modulate 
information in water is presented while magnetic nano particles 
are used as information carriers in [14]. However, While the 
testbeds in [13]  and  [14] consider testing parts of the body 
vessels, our experimental platform is built to mimic the human 
body environment and can provide prediction of MC status at 
different parts of the body and test different routes of MC 
singling into the human body. In addition, its predictions are 
validated against clinical trials, animal tests and analytical 
models. 
III. OVERVIEW OF PHARMACOKINETICS 
Pharmacokinetics (PK) is a branch of pharmacology that 
studies how the body affects molecule movements and 
concentration of Administered Substances (ASs), such as drugs, 
food additives or cosmetics to the body over time. PK models 
aim to mathematically predict the concentration profile over 
time for an AS affected by the bodily processes impacting the 
AS concentration in the body. 
A. Bodily Processes: 
The main bodily processes that affect ASs are absorption, 
distribution, metabolism and excretion (ADME). These 
processes determine the concentration of ASs in the blood and 
how it changes over time [25]. Once an AS is administered to 
the body, the absorption process moves the AS from the 
administration site to the circulatory system. There are many 
routes that an AS can take to enter the body such as oral, dermal, 
intravenous, or inhalation. The absorption rate depends on the 
chemical properties of the AS and the route of administration. 
From the route of administration, an AS diffuses passively 
through cells and membranes to reach the circulatory system 
which determines the extent of the absorption process. 
However, the absorption process is bypassed if an AS is 
administered intravenously as it directly enters the circulatory 
system. The blood then carries the AS and distributes it 
throughout the body. Once an AS reaches the blood, the 
metabolism and excretion processes start to eliminate the AS 
from the body and, therefore, the two processes are sometimes 
combined in a single process denoted elimination.  The 
elimination process continues till the AS is completely removed 
from the body or the natural level of the AS in the blood before 
administration takes place is retained to insure the body’s 
stability or homeostasis. The metabolization process denotes 
the biotransformation of chemical structure of an AS into other 
substances which mainly takes place in the liver. The excretion 
process filters ASs from the blood and is  preformed mainly by 
the kidneys and partially in the liver. 
B. PK Modeling: 
PK models mathematically estimate the concentration levels 
of an AS in the body over time [25]. The model represents the 
body as a set of interconnected compartments. It assumes that 
the rate of transfer of an AS into compartments and the rate of 
elimination from compartments due to ADME processes 
follows linear or first-order kinetics. The number of 
compartments is decided based on the observation of the AS 
concentration profile over time which depends on the AS 
physical and chemical properties and how the ADME processes 
act on it. In this study, we make two assumptions about ASs 
 
Fig.  1. One-compartment PK Model, (a) intravenous and (b) extravascular 
administration. 
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used for MC signaling. First, ASs are selected so that their 
physical and chemical properties allows them to rapidly 
distribute in the body. Therefore, the distribution process will 
not affect ASs and, more importantly, the model is simplified 
to enable us to represent the entire body as a single homogenous 
compartment that follows the one compartment PK model. 
While physiologically real AS concentrations in organs or 
tissues will be different than the estimated levels by the one 
compartment model, the model estimation of the change in 
concentration will quantitively reflect changes (increasing or 
decreasing) in all tissues.  Second, ASs are not bio transformed 
or metabolized, therefore, there will be no metabolization effect 
on our MC signal. 
Fig. 1 (a) and (b) show the one compartment PK model for 
intravenous and extravascular administrations respectively. 
ASs are assumed to be eliminated from the body in the first-
order process with elimination constant ke. The rate of dose 
elimination is proportional to the quantity of the dose remaining 
in the body. Depending on the rate and extent of absorption, the 
amount of AS in the body can be estimated based on the route 
of administration to the body.  
If an AS is administered in a place where it can reach the 
blood quickly, such as intravenous injection as shown in Fig 1 
(a), the absorption process will have no effect on the AS, and 
therefore, the AS concentration would only be subject to the 
elimination process. Using Fig. 1 (a), the rate of change in the 
amount of AS in the body would be given by 
𝑑𝐵
𝑑𝑡
= −𝑘𝑒B + IS (1) 
where IS is the input signal, B is the amount of the AS, and 𝑘𝑒 
is the first order elimination rate constant for the AS. The 
negative sign indicates decrease in the number of particles of 
AS. Solving (1) as in [12] yields the equation that predicts 
concentration over time: 
𝐶𝐵 =
B0
𝑉
𝑒−𝑘𝑒𝑡 (2) 
where B0 is the initial AS concentration at t = 0 and 𝑉 is the 
apparent volume of distribution. 
On the other hand, if an AS is given extravascular as shown 
in Fig.1 (b), (e.g. orally), it would reach the blood slowly and 
the absorption process will control how fast it goes into the 
body by a first-order absorption constant ka that is specific to 
the site of administration. For example, ka for oral 
administration will be different from ka for dermal 
administration. As a result, the AS amount in the body is 
controlled by the absorption and elimination processes and the 
rate of change of the AS in the administration and body 
compartment is given by 
𝑑𝐴
𝑑𝑡
= −𝑘𝑎𝐴 +  𝐹 IS (3) 
𝑑𝐵
𝑑𝑡
= 𝑘𝑎A − 𝑘𝑒B (4) 
where A is the amount of the AS at the administration site, 𝐹 is 
the absorbable fraction of 𝐴0, and 𝑘𝑎  is the first-order 
elimination rate constant for the AS from the administration 
site. Solving (3) and (4)  as in [12], we get 
𝐶𝐵 =
𝑘𝑎𝐹 𝐴0
𝑉 (𝑘𝑎 − 𝑘𝑒)
(𝑒−𝑘𝑒 − 𝑒−𝑘𝑎𝑡) (5) 
where 𝐴0 is total amount of AS administered at t = 0; and 𝑉 is 
the apparent volume of distribution. 
The values for 𝑘𝑒, 𝑘𝑎, 𝐹, and 𝑉 are estimated by obtaining 
the AS concentration profile over time for the patient and then 
using the method of residuals or the least squares curve fitting 
techniques [12].   
IV. IMPULSE RESPONSE OF BODY 
The PK model shown in Fig. 1 can be represented as an LTI 
system that consists of two internal LTI systems: the 
administration site compartment and the body compartment. 
The input to the system is a molecular signal and the output is  
the desired signal that conveys information. We are interested 
in finding the impulse response for two cases based on the 
location of the input signal introduction. The first case is 
intravenous administration when an input is directly injected 
into the body compartment, i.e., Fig.1 (a). The second case is 
extravascular administration when the input signal enters via 
the administration compartment, i.e., Fig.1 (b). Using the rate 
equations for each compartment, the impulse response of both 
cases are derived in this section.  
This system is a continuous LTI system for which its input 
and output satisfy a linear constant-coefficient differential 
equation of the form 
∑ 𝑎𝑘
𝑀
𝑘=0
𝑑𝑘𝑦(𝑡)
𝑑𝑡
=  ∑ 𝑏𝑘
𝑁
𝑘=0
𝑑𝑘𝑥(𝑡)
𝑑𝑡
. (6) 
Thus, the frequency response for each compartment can be 
obtained using the following equation from [26]: 
𝐻(𝑗𝜔) =  
𝑌(𝑗𝜔)
𝑋(𝑗𝜔)
=  
∑ 𝑏𝑘
𝑀
𝑘=0 (𝑗𝜔)
𝑘
∑ 𝑎𝑘
𝑀
𝑘=0 (𝑗𝜔)
𝑘
 (7) 
Considering the more general extravascular case, Fig. 1 (b), and 
using (3) at the administration site compartment, the frequency 
response is 
𝐻Admin(𝑗𝜔) =  
𝐹
(𝑘𝑎 + 𝑗𝜔)
. (8) 
 
Similarly, using (4), the frequency response of the body 
compartment is 
𝐻Body(𝑗𝜔) =  
𝑘𝑎
(𝑘𝑒 + 𝑗𝜔)
. (9) 
 
Therefore, the frequency response for the extravascular 
administration case is 
 
𝐻𝑒(𝑗𝜔) = 𝐻Admin(𝑗𝜔) 𝐻Body(𝑗𝜔)
=  
F
(𝑘𝑎 + 𝑗𝜔)
𝑘𝑎
(𝑘𝑒 + 𝑗𝜔)
, 
(10) 
and the time domain impulse response for the total amount of 
the dose is 
ℎ𝑒(𝑡) =
𝐹 𝑘𝑎
(𝑘𝑎  − 𝑘𝑒)
 (𝑒−𝑘𝑒𝑡 −  𝑒−𝑘𝑎𝑡). (11) 
Dividing by the volume we obtain the impulse response of the 
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system for the concentration 
ℎ𝑒𝑐(𝑡) =
𝐹 𝑘𝑎
𝑉 (𝑘𝑎 − 𝑘𝑒)
 (𝑒−𝑘𝑒𝑡 −  𝑒−𝑘𝑎𝑡). (12) 
 
Similarly, the frequency response intravenous administration 
case is 
𝐻𝑖(𝑗𝜔) =  𝐻𝐵𝑜𝑑𝑦(𝑗𝜔) =  
1
(𝑘𝑒 + 𝑗𝜔)
, (13) 
and the time domain impulse response for the total dose amount 
is 
ℎ𝑖(𝑡) = 𝑒
−𝑘𝑒𝑡 , (14) 
and dividing by the volume we obtain the impulse response of 
the system for the concentration 
V. PROPOSED MOSIME AND MOCOBO SYSTEM 
Like any traditional communication system, the proposed 
MoCoBo system consists of three main components: a 
transmitter, a channel, and a receiver as shown in Fig. 2.  
However, it differs in using the body as the communication 
channel and employing a new MoSiMe for information 
signaling, which requires changes to the design of the 
traditional communication system components. In the 
following subsections, the channel and MoSiMe will be 
presented. Then, we will characterize the properties, design 
requirements, and modifications to the transmitter and the 
receiver to support the new signaling method. 
A. The Channel 
The communication channel is the human body. Molecules 
travel from the transmitter’s side to the receiver’s side passively 
by drift and diffusion in the body liquids. The molecules 
propagate from site of release via diffusion till they arrive to the 
blood stream. Then, the blood carries and distributes them all 
over the body. Molecules diffuse slowly from the blood to 
different organs and tissues via means of diffusion based on 
concentration gradient. The body also starts to eliminate 
molecules from blood via elimination organs such as the liver, 
kidney and sweat glands which results in reducing molecule 
concentration in the body. Therefore, the concentration in the 
blood becomes less than other tissues and results in reverse 
diffusion of molecules from tissues to blood. The process of 
maintaining fixed levels of a specific concentration is called 
homeostats.  The process continues till the normal level of 
molecular concentration is reached within the body. 
B. MoSiMe In the Body 
The proposed system makes use of MoSiMe to send 
information through the body. MoSiMe exploits the effects of 
ADME processes on the AS to create a wave. Fig. 3 shows a 
typical wave generated in the body by this method where the 
concentration of AS molecules in the body represents the signal 
amplitude versus time. The wave has two phases: the rising 
phase and falling phase. The rising phase starts after injecting 
AS molecules into the body as the concentration starts to 
increase with a rate proportional to how fast the signaling 
molecules get absorbed by the body and reach the circulatory 
system. As the signaling molecules start entering the blood 
system, the body starts eliminating them out of the body by 
elimination organs such as the liver, kidneys or sweat glands or 
break them down into other compounds. If the injection of AS 
molecules stops, the elimination process starts the falling phase 
and leads to a decline in the signaling molecules’ concentration. 
By exploiting the bodily processes of absorption and 
elimination, a molecular wave can be generated by varying the 
number of molecules released at the transmitter with time which 
creates a signal that can modulate and carry information across 
the body as shown in Fig. 4. 
ℎ𝑖𝑐(𝑡) =
1
𝑉 
 𝑒−𝑘𝑒𝑡 . (15) 
Fig.  2. System-level model for in-body molecular communication 
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Fig.  3. Administered Substance (AS) concentration profile over time 
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C. The MoCoBo Transmitter: 
From the logical design point of view, The MoCoBo 
transmitter components are similar to any traditional transmitter 
components. It has an information source, a source encoder, a 
channel encoder, and a modulator as shown in Fig. 2. The 
information source has a set of messages to be sent to the 
receiver. The source encoder takes a message, converts it to its 
binary representation and passes it to the channel encoder where 
extra bits are added for error detection and correction. Streams 
of bits are then modulated and sent into the channel. 
The MoCoBo transmitter can be made of active components 
such as traditional transmitters or passive components which is 
an advantage of using MoSiMe for signaling.  
An active transmitter consists of a microcontroller, power 
source, AS reservoir and a releasing mechanism. The 
microcontroller is powered by the power source and is 
programmed to perform all the functions of a traditional 
transmitter except that it should have a mechanism to control 
the AS amount and release time based on the information to be 
modulated. The release mechanism could be controlled using a 
pump that is powered to administer molecules and switched off 
to stop.  
On the other hand, a passive transmitter could deliver a 
molecular signal without electrically powered parts utilizing 
physical and chemical properties of the body and the 
transmitter’s components. For the transmitter to generate a 
molecular signal that modulates information, it needs to control 
the AS released amount and time of release. This could be 
achieved using multiple compartments made of biodegradable 
materials. The compartments would hold different 
concentrations of the AS inside biodegradable walls with 
different dissolution time. The molecular signal can then be 
modulated by varying concentrations inside compartments, 
with the biodegradable walls controlling the time of release. 
Fig. 5 (a) shows an example of a passive 2-bits smart pill that 
can modulate two bits. The pill contains two compartments, 
denoted C1 and C2. Each compartment contains a solid or liquid 
form of an AS. The compartments are covered with membranes 
with different biodegradability constants and are made of 
different materials so that the dissolution time T1 of C1 is greater 
than the dissolution time T2 of C2. To modulate two bits of 
information, we need to have two levels of concentrations of 
the AS, denoted L0 and L1, where L0 is half of L1. By setting 
different combinations of L0 and L1 in the compartments, we 
can generate the molecular signal corresponding to 00, 01, 10, 
and 11 as shown in Fig. 4.  
There are many routes a molecular signal can take into the 
body, such as oral, dermal, intravenous, or inhaling or any other 
route used by regular medications. The molecular signal route 
of administration determines the MoCoBo transmitter form. For 
example, in oral administration the transmitter components can 
be enclosed in pill shaped containers so that they can be taken 
orally and work from inside the body as shown in Fig. 5 (a) and 
(c). Alternatively, dermal route can be used where the 
transmitter should be designed to work from out of the body by 
attaching it to the skin such as transmitters in Fig 5 (b) and (d). 
A passive transmitter can be realized in the form of a patch that 
has compartments storing the signaling molecules and 
controlling their release time using biodegradable material. The 
molecules would be carried from the compartments and 
injected into the body via micro needles. Fig. 5 (b) shows a 
passive 4-bits smart patch. 
 An active transmitter can be placed inside a small box with 
an infusion set that has a cannula is shown in Fig 5 (d). The 
 
Fig.  5. Different MoCoBo transmitters; (a) Passive 4-bits smart patch, (b) passive 2-bits smart pill, (c) Active smart pill, (d) Active portable transmitter  
 
(d) Active portable transmitter 
(b) Passive 4-bits smart patch (a) Passive 2-bits smart pill
Micro needles
Compartments 
with different 
biodegradability constants 
Power Source
MicrocontrollerAS storage
Pump
Infusion Set
Cannula
Patch
Compartment 1 (C2)
Low dissolving 
rate
Compartment 1 (C1)
High dissolving 
rate
Power Source
MicrocontrollerAS storagePump
(c) Active smart pill
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cannula is inserted through the skin till it reaches a fatty tissue 
and a patch is used to hold the cannula in place while delivering 
the AS to the body.  
There are advantages and disadvantages for passive and 
active transmitters. While passive transmitters are ideal for 
sending one-time short and pre-encoded messages, active 
transmitters have the flexibility to send many messages with 
longer lengths. Furthermore, active transmitters can support full 
duplex when equipped with a receiver module. However, active 
transmitters have higher costs and require a power source. 
D. The MoCoBo Receiver: 
The MoCoBo receiver has the same logical components of a 
traditional receiver: demodulator, channel decoder, source 
decoder, and an information sink as shown in Fig. 2. The 
receiver can be an Implanted Electronic Medical Device 
(IEMD) that has a microcontroller, power source, and a bio 
sensor. The microcontroller detects signals received by the 
biosensor and estimates the channel symbols.  It then runs the 
channel decoder to detect and correct errors in the transmitted 
stream of bits. After that, the source decoder predicts the 
message sent based on the estimated stream of bits. 
The main difference between the physical components of the 
MoCoBo receiver and traditional receivers is the demodulation 
method. MoCoBo receivers must be equipped with a biosensor 
that is capable of detecting the presence/absence of AS or 
measure the quantity or concentration of ASs. Therefore, the 
selection of ASs will dictate the appropriate type of biosensor 
used. For example, a metal-oxide sensor, currently used in an 
IEMD for measuring signals generated by glucose (sugar), 
could be placed in the interstitial tissue to measure glucose 
concentration [27], [28]. 
VI. MOCOBO EXPERIMENTAL PLATFORM 
We built an experimental MoCoBo platform to test the 
proposed MoCoBo system and method under constraints that 
mimic the human body environment. The platform can be used 
to test and verify new transmitters, receivers, or modulation 
techniques. The platform consists of two parts: the body 
modeling components and the communication ends 
components as shown in Fig. 6.  
A. Body Modeling Components 
The body modeling components consist of hardware and 
software parts that mimic the body physiological processes 
affecting a molecular signal. The current setup of the platform 
models two ADME processes which are the absorption and 
elimination that follow one-compartment PK model. It is also 
capable of testing different administration routes to the body 
such as oral and intravenous. The platform can be extended to 
model more complex PK models and ADME processes by 
adding more pumps and connections.  
We first present the assumptions used to build the platform, 
which constraints the selection of the signaling molecules. 
Then, we derive the equations for calculating the required flow 
rates between compartments to generate ADME parameters 
such as absorption and elimination constants (i.e. ka and ke). 
Finally, the platform setup and configurations are discussed. 
1) Assumptions: 
In designing the experimental platform, the following 
assumptions are made: 
• The signaling molecules get into the body and reach 
equilibrium rapidly.  
• Mixing the solution in the compartment makes the 
signaling molecules homogenous all over the compartment 
instantaneously. 
• The signaling molecules are not deformed or changed into 
other forms through metabolization or chemical reactions. 
Therefore, the rate of change in the concentration of the 
signaling molecules is directly proportional to its 
concentration in each compartment.  
The first two assumptions are widely accepted in 
pharmaceutical sciences for modeling drugs using a one-
compartment PK model [12],[29], which we have used as the 
basis for building this experimental platform. The third 
assumption is made to simplify the design of the experimental 
platform. However, the experimental platform can be extended 
to account for cases where the signaling molecules do not 
satisfy this assumption, by adding an output pump that accounts 
for loss of signaling molecules through metabolization or 
chemical reactions. 
2) Calculating Flow Rates 
Each AS has its absorption and elimination constants (i.e. ka 
and ke) that reflects how fast the body absorbs or eliminates it. 
 
Fig.  7. Experimental platform logical diagram of the body components for (a) 
intravenous administration and (b) extravascular administration. 
 
 
Fig. 6. MoCoBo experimental platform. 
Body Modeling Components
Communication Ends Components
Receiver Transmitter
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Therefore, we need to find the flow rates (denoted by 𝑄𝑎 and 
𝑄𝑒) and compartments’ volumes (denoted by Va and Vb) that 
correspond to those constants. Next, the relationship between 
absorption and elimination constants, flow rates, and 
compartment volumes will be derived for the case of 
extravascular administration. The same approach can be used 
for the intravenous administration, which will lead to the same 
relationships and hence that is omitted for brevity.   
From Fig. 7 (b), we derive the mass balance equations that 
determines the flow rates in terms of their corresponding 
constants. By the law of mass conservation [30], the mass 
balance equation for the administration compartment can be 
written as 
d 𝐴
dt
 =  𝑚𝑤 − 𝑚𝑎 + 𝑚𝐼  (16) 
where 𝐴 is the total mass accumulated in the administration 
compartment while 𝑚𝑊, 𝑚𝑎 , and 𝑚𝐼 are the rates of mass flow 
from the water compartment into the administration, from 
administration to the body compartment, and from the input 
into the administration compartment, respectively. Similarly, 
the mass balance equations for the body compartment can be 
written as 
d 𝐵
dt
 =  𝑚𝑎 − 𝑚𝑒 + 𝑚𝑤 (17) 
where B is the total mass accumulated in the body compartment 
while 𝑚𝑎, 𝑚𝑒, and 𝑚𝑤 are the rates of mass flow from the 
administration compartment into the body compartment, from 
the body compartment into the excreta compartment, and from 
the water compartment into the body compartment, 
respectively.  
At the beginning of the experiment and at steady state, 𝑚𝐼 is 
zero. Noting that the flow of mass is 
𝑚 = 𝑄 𝑐 (18) 
where Q is the volumetric flow in mL/sec and c is the 
concentration in particles per millions (ppm). Equations (16) 
and (17) can be rewritten as follows 
d 𝐴
dt
 =  𝑄𝑎  𝑐𝑤 −  𝑄𝑎  𝑐𝑎 (19) 
d 𝐵
dt
 =  𝑄𝑎  𝑐𝑎 −  𝑄𝑒  𝑐𝑏 +  𝑄𝑎  𝑐𝑤 (20) 
Where c𝑎 and c𝑏are the concentration in the body and 
administration compartments, and 𝑄𝑎 and 𝑄𝑒  are the volumetric 
follow rates from the administration to the body compartment, 
and from the body to the excreta compartment, respectively. To 
maintain constant volumes in the administration and body 
compartments, the volumetric flow rates from the water 
compartment to them is set to be equal to the outflows from the 
compartment.  However, 𝑐𝑤 is zero because the flow coming 
from the water compartment carries no signaling molecules. 
Therefore, (19) and (20) reduce to 
d 𝐴
dt
 = − 𝑄𝑎  𝑐𝑎 (21) 
d 𝐵
dt
 =  𝑄𝑎  𝑐𝑎 −  𝑄𝑒  𝑐𝑏 . (22) 
  
We also know that 
𝐴 = c𝑎 V𝑎 (23) 
𝐵 = c𝑏 V𝑏 (24) 
where V𝑎, and V𝑏 are the concentration and volume in the body 
and administration compartments, respectively. Substituting 
(23) and (24) in (21) and (22), and comparing that outcome with 
(3) and (4),we can be obtain 𝑄𝑎  and 𝑄𝑒  as: 
 
𝑄𝑎 =  𝑘𝑎V𝑎 (25) 
 
𝑄𝑒 =  𝑘𝑒V𝑏 . (26) 
3) Setup 
The platform consists of a set of beakers, magnetic stirrers, 
Arduino controllers, peristaltic pumps and connecting tubes as 
shown in Fig. 6. While any liquid that represents the body fluids 
such as blood can be used in the platform, water is used as the 
carrying medium since its properties are very similar to body 
fluids, primarily as it constitutes more than 60% of body mass 
and it is the main element of its fluids. In addition, it is easier 
and cheaper at this early stage of testing to deal with water 
compared with using real plasma or blood, which are not as 
accessible and require special care and treatment. However, we 
remark that the platform can use other carrier media, after 
appropriate adjustments to the calculation of flow rates as 
presented in the next subsection. 
Figs. 7 (a) and (b) illustrate the logical diagram of the body 
components for intravenous and extravascular administrations, 
respectively. They show how different parts are connected to 
each other and the flow rates between the compartments. In the 
case of intravenous administration, one beaker is used to 
represent the body compartment, while in the case of 
extravascular administration, two beakers are used to represent 
the administration and the body compartments. To maintain 
uniform distribution of the contents in the administration and 
body compartments, a magnetic stirrer is placed under each one 
of them. A large container filled with clear water is used to 
supply clean water to the administration and the body 
compartments. A large empty container is used to represent the 
excreta that collect waste removed from the body compartment. 
In the intravenous administration, shown in Fig. 7 (a), the 
dose goes into the body compartment and hence, is only subject 
to the elimination process. The elimination process is modeled 
by clearing water from the body compartment to the excreta 
container while adding an equal amount to the body 
compartment from the clean water container to maintain a 
constant volume of water in the body compartment. To achieve 
this, two pumps with equal flow rates (i.e. Qe as shown in Fig. 
7 (a)) are used, where one introduces clear water to the body 
compartment and the other draws water from it to the excreta 
container. The pumps’s flow rate is controlled by connecting 
them to a Qunqi L298N motor drive and controlling their 
speeds via software installed in the Arduino controller.  
In the extravascular administration, shown in Fig. 7 (b), the 
dose goes into the administration compartment and then moves 
to the body compartment. Therefore, it is subject to absorption 
and elimination processes. To model the two processes, three 
pumps with the same flow rate are used. The first moves clear 
water from the water source to the administration compartment,   
while the second pump moves solution from the administration 
compartment to the body compartment. The third pump is used 
to move the solution from the body compartment the excreta. 
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Using (25) and (26) for a given ka and ke, the volumes of the 
administration and body compartments (Va and Vb) are found 
and set while making the flow rates Qa and Qe equal. Since we 
use low cost pumps it is easier to achieve the same effect of 
having a given absorption and elimination constants (ka and ke) 
by fixing the flow rates (Qa and Qe) to the same value, then, 
finding the volumes of compartments (Va and Vb) for the 
selected values for ka, ke, Qa, and Qe. The pumps’ flow rate is 
again controlled using a Qunqi L298N motor drive controlled 
by software installed in the Arduino controller. 
At the beginning of every experiment, clean water is added to 
the administration, body, and water compartments and a sample 
is taken as a blank and its Total Dissolved Solids (TDS) reading 
is used as a zero for all the subsequent measurements of 
concentrations in the testing environment.    
 
B. Communication End Components 
An experimental MoCoBo transmitter and a MoCoBo 
receiver are built as follows to test MC in the experimental 
platform: 
1) The Transmitter: 
The transmitter consists of a container, signaling liquid, a 
pump, an Arduino controller, and a power source as shown in 
Fig. 6. The container stores the signaling liquid and uses 
peristaltic pump geared with a 12 Volt DC motor. The pump is 
connected to a Qunqi L298N motor drive that is controlled by 
the PWM Arduino port to control its speed as needed. The 
Arduino is programmed to convert a given stream of binary bits 
into a series of ON-OFF pump cycles where ON runs the pump 
and the signaling liquid is injected by the transmitter while an 
OFF stop the pump. The duration of ON and OFF states 
depends on the encoding scheme. 
Table salt is used as the source of generating signaling 
molecules because of its electrolyte properties when dissolved 
in water. The change of its concentration can be measured by 
the change of the conductance of the solution,  which simplifies 
the task of signaling and detection. In addition, it is a common 
substance consumed in food and does not have harmful side 
effects or toxicity to human body if the amount consumed is 
within the recommended daily intakes. We remark that, even 
though table salt is used, the constructed experimental platform 
is generally applicable to emulate molecular communication 
with all signaling molecules by setting the correct flow rates, as 
demonstrated in our experiments presented in Sec. VI.A.3. 
The main signaling molecules are Sodium (Na+) and Chloride 
(Cl-) ions plus other ions found in table salt such as iodine and 
calcium. Since it is not easy to control the release of precise 
amounts of solid form table salt, its liquid form is used by 
dissolving it in purified water.  
To prepare the signaling liquid, one gram of Winsor table salt 
is dissolved in each liter of Aquafina purified water that has an 
average of four TDS. Then, the TDS of the solution is measured 
to determine the concentration of dissolved particles in the 
solution. The Atlas Scientific Conductivity (ASC) kit with a K 
0.1 conductivity probe is used to determine the exact TDS of 
the formed liquid. 
2) The Receiver: 
The receiver consists of a conductivity sensor, Arduino 
controller, and power supply. The conductivity sensor, made by 
ASC, is connected to the Arduino controller and can measure 
TDS in liquids with temperature compensation. The Arduino 
controller is programmed to log readings from the sensor and 
send them to MATLAB via a serial port.  
VII. RESULTS 
A. Validating the Analytical Model 
To increase our confidence in the MoCoBo analytical model, 
its predictions for concentration levels over time are compared 
with clinical trial measurements and animal tests shown in Fig. 
8 and Fig. 9 respectively. Fig. 8 shows the Chlorphenesin 
Carbamate plasma concentration levels over time in human 
plasma after oral administration of 3g [12]. Similarly, Fig. 9 
shows measurements of the plasma concentrations of 
Vinpocetine after giving oral dose of 10mg/kg to a Wistar rat 
[31]. 
To validate the MoCoBo analytical model, the body is 
modeled as an LTI system with impulse response given by (14) 
where the values for F, V, ka, and ke are obtained from [12] and 
[31].  The dose is modeled as an input signal in the form of an 
impulse with a magnitude equivalent to the dose weight. 
MATLAB is used to generate the body response by convoluting 
the input signal (dose) with the impulse response. The output of 
the convolution is the plasma concentration for the given drug 
under the given system model. The results show satisfactory 
match between the modeled and the observed measurements for 
both the human and rat data. 
 
B. Validating the Experimental Platform Against Human 
Tests 
The predictions of the experimental platform are validated 
against the observed measurements of Chlorphenesin 
Carbamate oral dose given to a Human, which is shown also in 
Fig. 9.  
Using (25) and (26), the body pump flow rates and 
compartment volumes are set as shown in Table I to generate 
the same of effect the absorption and elimination constants (ka 
and ke) of Chlorphenesin Carbamate in a human. Then, a dose 
of 1 g of table salt is added to the administration compartment. 
The concentration of table salts are measured and scaled by a 
factor of 5.595 x 10-2 to mimic the effect of a 3g oral dose of 
Chlorphenesin Carbamate. The results show satisfactory match 
between the experimental platform and the observed 
measurements. 
C. Validating the Experimental Platform Against Animal 
Tests 
The predictions of the experimental platform are validated 
against the observed measurements of Vinpocetine oral dose 
given to a Wistar rat, as shown in Fig. 9.  
Using (25) and (26), the pump flow rates and compartment 
volumes are set as shown in Table II to generate the same effect 
of the absorption and elimination constants (ka and ke) of 
Vinpocetine in a Wistar. Then, a dose of 522 mg of table salt is 
 
Fig.  9. Modeled vs. Observed vs. Experimental Platform Vinpocetine plasma 
concentration after giving oral dose of 10mg to a Wistar rat. 
 
 
 
Fig.  9. Modeled vs. Observed vs. Experimental Platform Vinpocetine plasma 
concentration after giving oral dose of 10mg to a Wistar rat. 
 
 
10 
> REPLACE THIS LINE WITH YOUR PAPER IDENTIFICATION NUMBER (DOUBLE-CLICK HERE TO EDIT) < 
 
added to the administration compartment. The concentration of 
table salts are measured and scaled by a factor of 1.501 x 10-3 
to mimic the effect of a 10mg/kg oral dose of Vinpocetine. The 
results show satisfactory match between the experimental 
platform and the observed measurements. 
D. Validating the Experimental Platform Against the 
Analytical Model 
The analytical model is already validated against trial 
measurements and animal tests as shown in Fig. 8 and Fig. 9. 
Therefore, the experimental platform is validated against the 
analytical model predictions when testing the MoCoBo system.  
For further testing, the analytical model is fed with the 
experimental platform parameters listed in Table III. The 
absorption and elimination constants (ka and ke) are calculated 
using (25) and (26). The impulse response is then calculated for 
intravenous and extravascular administration using (11) and 
(14) respectively.  To generate the impulse response for the 
experimental platform, an input signal should be created to 
resemble a delta signal that has infinite magnitude and zero 
width. To achieve this, a 130 mg dose of table salt is prepared. 
To reduce the width of the signal, the dose is put very quickly 
in a one-shot manner to generate the required impulse effect. 
The impulse signal is input into the body compartment to 
generate the impulse response for intravenous administration. 
The same procedure is repeated to generate the impulse 
response for the extravascular administration by releasing the 
impulse signal in the administration compartment.  
The analytical and experimental normalized impulse response 
for the intravenous and extravascular administration are plotted 
in Fig. 10. which shows that the modeled and experimental 
impulse responses are matching. 
E. Testing MoCoBo Communication 
Our goal is to demonstrate that information can be sent using 
the proposed MoCoBo system and method. The main difference 
between the MoCoBo system and conventional communication 
systems lies in the use of molecular waves instead of 
electromagnetic waves while all other functionalities remain the 
same. Therefore, no testing is performed on common 
components such as the information sources and channel 
encoding in the transmitter and their counterparts in the receiver 
side. Instead, our focus is centered around testing the 
modulation, propagation, and demodulation components in the 
body using molecular communication where we aim to provide 
a proof of concept for the proposed system and method.  
A predefined binary stream of bits (111-01010011) is 
modulated and demodulated using the proposed system and 
method. The binary stream consists of 11 bits where it starts by 
three ones to signal the start of communication, then 8 bits that 
represent the data part, which was selected to cover all possible 
combinations of two bits.   
 The modulation of bits is achieved by changing the 
concentration of the signaling molecules released in the body 
where a 1 is represented by releasing a dose and a 0 is 
represented by no dose. The dose representation for the input 
signal is plotted in Fig. 11, where the magnitude represents the 
amount of dose. Two scenarios are tested. In the first, the 
transmitter has direct access to the blood stream and hence the 
input signal is applied to the body compartment, thus 
mimicking an intravenous administration. In the second, the 
transmitter is assumed to be placed in the stomach or a muscle 
and therefore, the input signal is applied to the administration 
compartment to test extravascular administration.   
The modeled body response to the input signal is found by 
convoluting the prepared input signal with the impulse 
response. On the other hand, the experimental body response to 
the input signal is captured by measuring the concentration of 
the signaling molecules’ levels at the receiver. The modeled and 
experimental body responses to the input signals are shown in 
Fig. 12 for the intravenous and extravascular administrations. 
We observe that the modeled response closely matches the 
experimental response despite some noise and spikes found in 
the experimental measurements. The spikes could be attributed 
 
Fig.  8. Modeled vs. Observed vs. Experimental Platform Chlorphenesin 
Carbamate plasma concentration after giving oral dose of 3g to a Human. 
 
 
 
Fig.  9. Modeled vs. Observed vs. Experimental Platform Vinpocetine plasma 
concentration after giving oral dose of 10mg to a Wistar rat. 
 
 
 
Fig.  10. The analytical and experimental normalized impulse response for the 
intravenous and extravascular administration 
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to the mechanical noise generated by moving parts and 
switching the transmitter’s pump on and off rapidly while 
modulating the input signal. 
The input signal is recovered at the receiver’s side by 
deconvoluting the body response with the impulse response of 
the body. Deconvolution is performed with the experimental 
impulse response and modeled impulse response, and their 
results are compared. As a reference for validating the 
recovered experimental input signal, the theoretical input signal 
is recovered by deconvoluting the modeled response with the 
modeled impulse response. The recovered signals are plotted in 
Fig. 13 for the case of intravenous administration and Fig. 14 
for the case of extravascular administration. The recovered 
signal has sharp spikes in places where 1’s are modulated and 
zero elsewhere, which resembles our choice of modulation. The 
magnitude of the recovered signal is less than the initial signal 
since in the current experimental setup, doses are introduced 
into the system by a pump with a constant flow rate which 
generates a pulse like signal rather than an impulse signal.  
VIII. SUMMARY, CONCLUSIONS AND FUTURE WORK 
Recently, MC has been recognized as an enabling technology 
for nanonetworks [1], where MC is envisioned to enable 
nanorobots to achieve sophisticated and complex tasks in the 
human body for promising medical applications. Many MC 
methods between nanorobots in the human body have been 
proposed and modeled in the literature. Here, we propose a new 
method and system for Molecular Communication in the Body, 
denoted MoSiMe and MoCoBo, respectively. The method takes 
advantage of how the bodily ADME affects drugs, referred to 
as Pharmacokinetics (PK) in pharmacology, to enable MC in 
between any points of the human body regardless of their 
distance even if they are in different parts of the body and even 
if they are separated by tissues and fluids. 
The MoCoBo system components and functionality are 
discussed in the context of traditional communication systems 
while explaining the differences and changes required due to 
the utilization of the new signaling method which we denote 
MoSiMe. MoSiMe employs ADME bodily processes such as 
absorption and elimination to realize signaling that conveys 
information between a transmitter and a receiver using 
molecules. Different designs for MoCoBo transmitters and 
receivers are proposed. Unlike traditional communication 
transmitters that must have active components, MoCoBo allows 
for creating passive transmitters that makes use of the chemical 
and physical properties of the signaling molecules and 
propagation environment. While traditional transmitters must 
work with a power source, we proposed for the first time in 
telecommunication design the concept of passive transmitters. 
In addition, we adapt a physical channel model for the human 
body from pharmacology, where kinetics of drug and its 
behavior after giving a dose to a patient are studied. Our model 
describes the body as an LTI system characterized by the body 
physiological PK parameters and the signaling molecules 
released into the body are input to the system. The output of the 
system is the body response, which is represented by the 
concertation levels in the body over time. The model results are 
validated against two different drugs given orally to a human 
and a rat which show satisfactory match. 
Conducting trials on human and animals is difficult for 
communication engineers as they lack the expertise and 
equipment in this field, which requires special facilities and 
procedures to perform. Therefore, we built an experimental 
platform to test the MoCoBo system and method. The platform 
consists of two components: one that models the body ADME 
processes and physical channel of the body while the other 
represents the communication ends. The platform is validated 
by comparing its response to clinical trials, animal tests and the  
 
Fig. 11. Dose representation for the input signal 111-01010011. 
 
Fig.  12. The modeled and experimental body response to the input signal for 
intravenous and extravascular administrations. 
 
 
Fig.  13. The modeled and experimental recovered input signal for intravenous 
administrations. 
 
 
Fig.  14. The modeled and experimental recovered input signal extravascular 
administrations. 
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TABLE I 
EXPERIMENTAL PLATFORM PARAMETERS FOR PREDICTING CHLORPHENESIN 
CARBAMATE PLASMA CONCENTRATION IN HUMAN 
Symbol Quantity Value 
Qa Absorption flow rate 1.025 x 10
-1  mL/s 
Qe Elimination flow rate 1.025 x 10
-1  mL/s 
Va Volume of administration 
compartment 
355 mL 
Vb Volume of body compartment 2.292 x 10
3   mL 
ka Absorption constant 2.89 x 10
-4 s-1 
ke Elimination constant 4.47 x 10
-5 s-1 
 
TABLE II 
EXPERIMENTAL PLATFORM PARAMETERS FOR PREDICTING VINPOCETINE 
CONCENTRATION IN WISTAR RAT 
Symbol Quantity Value 
Qa Absorption flow rate 1.025 x 10
-1  mL/s 
Qe Elimination flow rate 1.025 x 10
-1  mL/s 
Va Volume of administration 
compartment 
605 mL 
Vb Volume of body compartment 202 mL 
ka Absorption constant 1.69 x 10
-4 s-1 
ke Elimination constant 5.08 x 10
-4 s-1 
TABLE III 
EXPERIMENTAL PLATFORM AND ANALYTICAL PARAMETERS FOR TESTING 
MOCOBO SYSTEM 
Symbol Quantity Value 
Qa Absorption flow rate 9.8 x 10
-1  mL/s 
Qe Elimination flow rate 9.8 x 10
-1  mL/s 
Va Volume of administration 
compartment 
650 mL 
Vb Volume of body compartment 300 mL 
ka Absorption constant 3.27 x 10
-3 s-1 
ke Elimination constant 1.51 x 10
-3 s-1 
analytical response of the body. One compartment PK model is 
tested using the platform and the results are matching the results 
predicted by the analytical model. Our results further show that 
messages can be sent between two devices using the proposed 
system. Two scenarios for transmitter placement are 
experimented based on the ability to access blood directly or 
indirectly, which we refer to as intravenous and extravascular 
administration. The first assumes that the transmitter has a 
release mechanism such as a needle connected directly to blood 
flow and can release the signaling molecules to it. The second 
assumes that the transmitter releases the signaling molecules in 
a part of the body that does not have direct access to the blood 
such as small intestines or muscles.  The platform can be easily 
extended to support more complicated PK models with more 
compartments. It can also be used to test different modulation 
schemes, new MoCoBo transmitters, and new MoCoBo 
receivers. 
There are many open issues that we propose as future work. 
The main issues can be divided into four categories. The first is 
related to the safety of using MC in the human body. Not any 
molecules will be suitable for signaling as some substances, 
when exceeding certain levels, might cause poisoning while 
others might interfere with natural body signaling processes. 
The second is related to data rates requirements of MC since it 
has very low data rates, which might require developing new 
communication protocols suitable for the available bandwidth. 
The third is related to transmitter design. In MC, passive 
transmitters can be created, which is not possible with electro-
magnetic communications. In addition, the placement of a 
transmitter in the body opens many issues and challenges. 
Moreover, a transmitter might have a limited amount of 
signaling molecules, which calls for efficient modulation 
techniques. The fourth category is related to the receiver design.  
The receiver must be equipped with a biosensor that matches 
the signaling molecules used by the transmitter, which opens 
the door for many choices and options.   
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